vapreotide [8621]
vapreotide
| SMILES | CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccccc2)CSSCC(C(=O)NC(Cc2c[nH]c3ccccc23)C(N)=O)NC1=O |
| InChIKey | SWXOGPJRIDTIRL-UHFFFAOYSA-N |
| Sequence | FCYWKVCW |
| HELM | PEPTIDE1{(F,[dF]).(C,[dC]).(Y,[dY]).(W,[dW]).(K,[dK]).(V,[dV]).(C,[dC]).(W,[dW]).[am]}$PEPTIDE1,PEPTIDE1,2:R3-7:R3$$$V2.0 |
Chemical Properties
| Hydrogen bond acceptors | 13 |
| Hydrogen bond donors | 13 |
| Rotatable bonds | 18 |
| Log P | 2.012 |
| Molecular weight (Da) | 1130.5 |
| Stereochemistry info | unspecified |
Bioactivities
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Gene | Species | Family | Class | Type | Min | Avg | Max | Database |
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Gene | Species | Family | Class | Type | Min | Avg | Max | Database |
vapreotide
Drug properties
| Molecular type | Peptide |
| Physiological/Surrogate | Surrogate |
| Approved drug | Yes |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV
9
Sankey plot
Drug Information
| Target | Disease | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene | Protein | Receptor family | Ligand type | Class | Name | Phase | ICD11 | ATC | Association score |